AstraZeneca announced that the China National Medical Products Administration has officially approved Truqap (English trade name: Truqap, generic name: Capisetib tablets) combined with Fulvestrant for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one endocrine therapy in the metastatic stage, or who have relapsed during adjuvant therapy or within 12 months after completing adjuvant therapy, and who are hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative and have one or more PIK3CA/AKT1/PTEN changes.